|
|
|
| Comparison of effect of Rosuvastatin and Atorvastatin on myocardial injury, inflammatory factors and soluble P selectin in patients with unstable angina pectoris after PCI |
| MOU Ying1 MA Chunhua2▲ |
1.Department of Internal Medicine Cardiovascular, Mianyang Central Hospital, Sichuan Province, Mianyang 621000, China;
2.Department of Respiration, Mianyang Central Hospital, Sichuan Province, Mianyang 621000, China |
|
|
|
Abstract Objective To investigate the effect of Rosuvastatin and Atorvastatin on myocardial injury, inflammatory factors and soluble P selectin (sP-S) in patients with unstable angina pectoris after PCI. Methods From December 2015 to October 2017, in Mianyang Central Hospital, 100 patients with UAP undergoing PCI were selected, according to random number table method, they were divided into Atorvastatin group (50 cases) and Rosuvastatin group (50 cases). Two groups were treated with general care one week before surgery, and then, the atorvastatin group was treated with 20 mg/d Atorvastatin for 7 d, the Rosuvastatin group was treated with 10 mg/d rosuvastatin for 7 d. The indexes levels of cardiac injury, inflammatory factors and sP-S in two groups were compared. Results About indexes of cardiac injury, 24 h after operation, the level of cTnI and CK-MB in Atorvastatin group were significantly higher than before medication (P < 0.05), and these were significantly higher than Rosuvastatin group at the same period (P < 0.05). About inflammatory factors, the level of TNF-α, IL-6 and hs-CRP in Atorvastatin group were significantly higher than before medication, and these were significantly higher than Rosuvastatin group at the same period (P < 0.05); the level of IL-10 of two groups were significantly higher than before medication, and that of Rosuvastatin group was much higher than Atorvastatin group (P < 0.05). The level of sP-S of the two groups was significantly increased, and that of Atorvastatin group was much higher than Rosuvastatin group (P < 0.05). Conclusion Before the implementation of PCI, it can more significantly decrease the level of inflammatory factors and improve myocardial injury that UAP patients were given Rosuvastatin than Atorvastatin.
|
|
|
|
|
|
[1] Kizilirmak F，Gunes HM，Demir GG，et al. Impact of intracoronary adenosine on myonecrosis in patients with unstable angina pectoris undergoing percutaneous coronary intervention [J]. Cardiovasc Drugs Ther，2015，29（6）：519-526.
[2] 张昕，李爱华，张振刚，等.阿托伐他汀对不稳定性心绞痛患者PCI术后心肌的保护作用[J].江苏医药，2015，41（24）：2945-2947.
[3] 黄靖，鲁玉明.老年急性ST段抬高型心肌梗死患者不同时机行经皮冠状动脉介入支架植入及心血管不良事件对比[J].中国老年学杂志，2018，38（1）：61-63.
[4] 李新峰，张领，蔡华，等.他汀类药物对经皮冠状动脉介入治疗患者术后短期肾功能及炎性指标的影响[J].中国临床保健杂志，2018，21（1）：78-80.
[5] 王江友，李浪，苏强，等.强化阿托伐他汀对经皮冠状动脉介入治疗围术期淋巴细胞的磷酸酶基因表达的影响[J].中国循环杂志，2013，28（8）：602-606.
[6] 柯元南，陈纪林.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志，2007，35（4）：295-304.
[7] 付艳东，赵翠萍.PCI术后心肌缺血损伤机制与治疗的研究进展[J].现代生物医学进展，2012，12（35）：6992-6994.
[8] 王小维，贾大林，齐国先.心肌肌钙蛋白Ⅰ测定对于不稳定型心绞痛患者微小心肌损伤的临床价值[J].中国医师进修杂志，2014，37（31）：41-43.
[9] 马洪梅.新生儿窒息心肌损伤血清CK-MB和cTnT的变化及其意义[J].海南医学院学报，2014，20（5）：694-696.
[10] Li X，Chen C，Feng G，et al. Plasma NT pro-BNP，hs-CRP and big-ET levels at admission as prognostic markers of survival in hospitalized patients with dilated cardiomyopathy：a single-center cohort study [J]. Bmc Cardiovascular Disorders，2014，14（7）：C197.
[11] 黄山，张程，陈艳，等.联合检测炎症因子IL-6、TNF-α和MCP-1对冠心病临床诊断价值[J].中国实验诊断学，2012，16（6）：1083-1085.
[12] 周琳，周光炎，路丽明.IL-10的双向免疫调节作用[J].细胞与分子免疫学杂志，2012，28（10）：1100-1102.
[13] 杨磊，余信国，刘俊超，等.瑞舒伐他汀辅治冠心病介入术后患者的疗效及其对血清 IGF-Ⅰ、E-selectin、TGF-β1水平的影响[J].疑难病杂志，2017，16（1）：6-9.
[14] 吕岩丽.瑞舒伐他汀联合氯吡格雷对不稳定型心绞痛患者血脂及hs-CRP水平的影响[J].中国医药科学，2016， 6（13）：76-78.
[15] 汪丽丽，贺钰梅，郝春举.瑞舒伐他汀联合辅酶Q10治疗慢性心衰后血清炎性指标、血清脑钠肽及心功能的变化[J].中国医药导报，2016，13（6）：166-169.
[16] 杨大柳，陈本敦.瑞舒伐他汀和阿托伐他汀对冠心病患者的调脂作用及其机制[J].中国当代医药，2016，23（18）：93-95.
[17] 余湘宁，黄宇辉，曾波，等.不同剂量瑞舒伐他汀对不稳定性心绞痛患者介入治疗围术期心肌损伤及炎性因子的影响[J].中华老年心脑血管病杂志，2014，16（4）：431-433.
[18] 陈文，程芳洲.瑞舒伐他汀与阿托伐他汀对急性心肌梗死患者PCI治疗后血清炎症因子表达的影响[J].岭南心血管病杂志，2013，19（4）：417-420.
[19] Barabash S，Norberg O. Strawberry extract presents antiplatelet activity by inhibition of inflammatory mediator of atherosclerosis（sP-selectin，sCD40L，RANTES，and IL-1β） and thrombus formation [J]. Platelets，2014，26（3）：224-229.
[20] 李华.急性冠脉综合征PCI前瑞舒伐他汀干预治疗的心肌保护作用研究[J].现代预防医学，2014，41（1）：180-182.
[21] 吴萃荣，王湛.瑞舒伐他汀与阿托伐他汀对急性心肌梗死患者PCI术后左室重构及近期预后影响的比较[J].实用医学杂志，2015，31（3）：470-472.
[22] 龚勇，葛广豪，马江伟，等.不同负荷量他汀类药物对急性心肌梗死直接PCI术后心肌细胞的影响[J].中国心血管病研究，2016，14（11）：1038-1043.
[23] 简春燕，黄自明，钟国荣，等.瑞舒伐他汀对急诊PCI术患者Hcy、hs-CRP及心脏结构、功能与预后的影响[J].广东医学，2015，36（17）：2742-2744.
[24] 沈娜，杨增芯.瑞舒伐他汀对行PCI术急性心肌梗死患者血清cTNI、Cys-C、Hcy 及心肌酶、炎症因子水平的影响[J].海南医学院学报，2016，22（21）：2544-2547. |
|
|
|
